Tioga Pharmaceuticals and Ono Pharmaceutical Co., Ltd. have entered an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline. Ono is responsible for developing and commercializing asimadoline in Japan, South Korea and Taiwan. Ono’s initial development of asimadoline will focus on diarrhea predominant irritable bowel syndrome (D-IBS). Tioga will receive an upfront ...